Provided by Tiger Fintech (Singapore) Pte. Ltd.

IGM Biosciences

1.13
+0.0000
Post-market: 1.11-0.0200-1.77%19:47 EDT
Volume:226.41K
Turnover:257.42K
Market Cap:67.55M
PE:-0.35
High:1.19
Open:1.12
Low:1.11
Close:1.13
Loading ...

IGM Biosciences upgraded to Neutral from Underweight at JPMorgan

TIPRANKS
·
11 Jan

IGM Biosciences Halts Antibody Therapies, Cuts Workforce

TIPRANKS
·
11 Jan

BUZZ-IGM Bio hits record low after development of two autoimmune drugs halted

Reuters
·
11 Jan

IGM Biosciences Shares Drop 68% as Company Halts Key Programs and Cuts Workforce

GuruFocus.com
·
11 Jan

IGM Biosciences Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $2 From $48

THOMSON REUTERS
·
11 Jan

IGM Biosciences Cut to Hold From Buy by Stifel

Dow Jones
·
11 Jan

Jefferies downgrades IGM Biosciences (IGMS) to a Hold

TIPRANKS
·
11 Jan

Dow Dips 500 Points; US Economy Adds 256,000 Jobs In December

Benzinga
·
10 Jan

IGM Biosciences Shares Down 69% at $1.95 After Co to Discontinue Development of Autoimmune Drugs

THOMSON REUTERS
·
10 Jan

IGM Biosciences price target lowered to $2 from $12 at Truist

TIPRANKS
·
10 Jan

Pre-Bell | US Futures Rise Before Jobs Report; WTI Futures up 3%; Nvidia Falls 2%; Quantum Computing Shares Pare Gains; Delta Air Gains 8%

Tiger Newspress
·
10 Jan

Analysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Abivax SA Sponsored ADR (ABVX)

TIPRANKS
·
10 Jan

BUZZ-IGM Bio tumbles as co halts development of 2 autoimmune drugs

Reuters
·
10 Jan

IGM Biosciences Shares Down 69% at $1.92 Premarket After Co to Discontinue Development of Autoimmune Drugs

THOMSON REUTERS
·
10 Jan

Truist Cuts Price Target on IGM Biosciences to $2 From $12, Keeps Hold Rating

MT Newswires Live
·
10 Jan

IGM Biosciences Inc : Bmo Cuts to Market Perform From Outperform; Cuts Target Price to $2 From $21

THOMSON REUTERS
·
10 Jan

IGM Biosciences Inc : Guggenheim Cuts to Neutral From Buy

THOMSON REUTERS
·
10 Jan

RBC Downgrades IGM Biosciences to Sector Perform From Outperform, Slashes Price Target to $1.50 From $20, Keeps Speculative Risk Qualifier

MT Newswires Live
·
10 Jan

IGM Biosciences Shares Down 69% Following Treatment Development Halt, Workforce Reduction

Dow Jones
·
10 Jan

IGM Biosciences downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
10 Jan